Pneumonia in Non-Hodgkin's Lymphoma After Rituximab-based Chemotherapy: a Case Series

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Aug 15

PMID 35966314

Authors

Qianying Zhang

Liang Han

Yuanyuan Lin

Xiaohong Sun

Haige Ye

Honglan Qian

Lan Sun

Songfu Jiang

Bin Liang

Affiliations

Soon will be listed here.

Abstract

Background: The incidence of pneumonia (PCP) has been increasing in patients with hematologic malignancies due to the use of glucocorticoid therapy and immunosuppressive medication. The reports of PCP in non-Hodgkin's lymphoma (NHL) after rituximab-based chemotherapy are still rare. We reported a case series of PCP in NHL to show the clinical features and prognosis in those patients.

Methods: We conducted a retrospective review of 15 NHL patients who developed PCP after rituximab-based chemotherapy during June 30, 2014 to June 1, 2020. We analyzed the laboratory and radiographic findings for those patients through descriptive statistics analysis.

Results: The study revealed that PCP in NHL patients was complicated by chemotherapy after about 4 courses (range, 2 to 6 courses). Most patients had a standard lymphocyte count before treatment, and 14 of 15 patients (93.3%) had lymphopenia at the time of diagnosis of PCP. In addition to typical symptoms such as fever and dyspnea at the diagnosis of PCP, most patients had abnormal laboratory indexes such as marked elevations of C-reactive protein (CRP) and lactic dehydrogenase (LDH) both before and at the time of diagnosis. The (1,3)-β-D-glucan test was also revealed as a sensitive index for PCP. Bilateral ground-glass opacity was detected in 14 cases through computed tomography (CT) scans. Positive results of microbiological testing were observed in 7 cases; sputum culture was positive in 3 and next-generation sequencing (NGS) was positive in 3 of these 7 patients, and the other case was positive in both sputum culture and NGS. Patients received high-dose trimethoprim/sulfamethoxazole (TMP/SMZ), caspofungin, and steroids as the treatment for PCP. Ventilatory support was required by 3 patients, so they were admitted to the intensive care unit (ICU), and 1 patient died from PCP.

Conclusions: Dynamic monitoring of CRP, LDH, and (1,3)-β-D-glucan test during the treatment of NHL may have a predictive value for the diagnosis of PCP. Additionally, we should use NGS as a rapid and sensitive method for the early diagnosis of PCP. When patients are classified as 'probable PCP', early and effective treatment has obvious significance to improve the prognosis.

Citing Articles

Risk of Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study.

Cheng Y, Huang C, Gau S, Chung N, Huang S, Huang C J Fungi (Basel). 2023; 9(1).

PMID: 36675844 PMC: 9866281. DOI: 10.3390/jof9010023.

References

Lands L . New therapies, new concerns: rituximab-associated lung injury. Pediatr Nephrol. 2010; 25(6):1001-3. DOI: 10.1007/s00467-010-1476-3. View

Hardak E, Oren I, Dann E, Yigla M, Faibish T, Rowe J . The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience. Acta Haematol. 2011; 127(2):110-4. DOI: 10.1159/000334113. View

White P, Backx M, Barnes R . Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017; 15(5):435-447. DOI: 10.1080/14787210.2017.1305887. View

Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P . Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol. 2002; 117(2):379-86. DOI: 10.1046/j.1365-2141.2002.03419.x. View

Kamel S, OConnor S, Lee N, Filshie R, Nandurkar H, Tam C . High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010; 51(5):797-801. DOI: 10.3109/10428191003699860. View

Kim Y, Kim J, Kim D, Ko Y, Choi J, Shin S . Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab. BMC Nephrol. 2020; 21(1):93. PMC: 7066802. DOI: 10.1186/s12882-020-01750-8. View

Tian Q, Si J, Jiang F, Xu R, Wei B, Huang B . Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection. HIV Med. 2020; 22(4):307-313. PMC: 7984216. DOI: 10.1111/hiv.13013. View

Chang H, Shih L, Wang C, Chuang W, Chen C . Granulomatous Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Acta Haematol. 2009; 123(1):30-3. DOI: 10.1159/000261020. View

Ward M, Donald F . Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999; 42(4):780-9. DOI: 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M. View

10.

Classen A, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff L . Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and.... Ann Hematol. 2021; 100(6):1603-1620. PMC: 8116237. DOI: 10.1007/s00277-021-04452-9. View

11.

Cooley L, Dendle C, Wolf J, Teh B, Chen S, Boutlis C . Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014; 44(12b):1350-63. DOI: 10.1111/imj.12599. View

12.

Kim H, Shin K, Lee J . Single nodular opacity of granulomatous pneumocystis jirovecii pneumonia in an asymptomatic lymphoma patient. Korean J Radiol. 2015; 16(2):440-3. PMC: 4347280. DOI: 10.3348/kjr.2015.16.2.440. View

13.

Mansharamani N, Garland R, Delaney D, Koziel H . Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000; 118(3):704-11. DOI: 10.1378/chest.118.3.704. View

14.

Wang Z, Liu X, Wang Q, Chen N, Tong S . A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole. Medicine (Baltimore). 2019; 98(23):e15997. PMC: 6571266. DOI: 10.1097/MD.0000000000015997. View

15.

Yale S, Limper A . Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71(1):5-13. DOI: 10.4065/71.1.5. View

16.

Damiani C, Gal S, Da Costa C, Virmaux M, Nevez G, Totet A . Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013; 51(10):3380-8. PMC: 3811637. DOI: 10.1128/JCM.01554-13. View

17.

Sepkowitz K, Brown A, Telzak E, Gottlieb S, Armstrong D . Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992; 267(6):832-7. View

18.

Juarez-Salcedo L, Dalia S . Indolent non-Hodgkin lymphoma treatment in the new drugs era. Chin Clin Oncol. 2020; 9(6):81. DOI: 10.21037/cco.2020.01.01. View

19.

Vogel M, Vatlach M, Weissgerber P, Goeppert B, Claussen C, Hetzel J . HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol. 2011; 81(6):1315-20. DOI: 10.1016/j.ejrad.2011.02.052. View

20.

Gaborit B, Tessoulin B, Lavergne R, Morio F, Sagan C, Canet E . Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Ann Intensive Care. 2019; 9(1):131. PMC: 6881486. DOI: 10.1186/s13613-019-0604-x. View